In an interview with Targeted Oncology, Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed which ...
Joseph Mikhael, MD, MEd, highlights the clinical and logistical advantages of the novel on-body injector developed for the ...
Dr. Monty Pal discusses how the increasing use of adjuvant immunotherapy has introduced new considerations for the management ...
Joseph Mikhael, MD, MEd, describes the impact of the FDA's approval of subcutaneous isatuximab with an on-body injector device. Joseph Mikhael, MD, MEd, professor in the Applied Cancer Research and ...
KOMET-007 shows ziftomenib plus venetoclax/azacitidine drives deep MRD-negative remissions in R/R AML, with manageable ...
Dr. Monty Pal summarizes his practical first-line treatment algorithm for advanced renal cell carcinoma (RCC), highlighting ...
A 940-patient real-world study confirms alectinib outperforms crizotinib in ALK-positive NSCLC, mirroring results from the ...
KOMET-007 tests ziftomenib with venetoclax and azacitidine in relapsed/refractory AML, selecting 600 mg to boost responses ...
Approval addresses the ~60% of HR+/HER2− advanced cases of patients with PIK3CA wild-type disease who are ineligible for PI3Kα-selective inhibitors. VIKTORIA-1 met primary PFS end points with ...
OptiTROP-Lung06 demonstrated statistically significant, clinically meaningful PFS improvement for sac-TMT plus pembrolizumab versus pembrolizumab plus pemetrexed/platinum in first-line driver-negative ...
The Himalayas-1 trial will investigate rinzimetostat in combination with darolutamide in patients who previously received abiraterone for metastatic castration-resistant prostate cancer. A phase 3 ...
KEYNOTE-C93 demonstrated BICR-assessed PFS superiority for pembrolizumab monotherapy over platinum doublet chemotherapy in frontline dMMR advanced/recurrent endometrial cancer. Overall survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results